PMC:7601109 / 34001-34908
Annnotations
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T35","span":{"begin":90,"end":104},"obj":"Body_part"},{"id":"T36","span":{"begin":98,"end":104},"obj":"Body_part"},{"id":"T37","span":{"begin":443,"end":459},"obj":"Body_part"},{"id":"T38","span":{"begin":448,"end":459},"obj":"Body_part"},{"id":"T39","span":{"begin":448,"end":452},"obj":"Body_part"},{"id":"T40","span":{"begin":556,"end":561},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"uberon_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"A36","pred":"uberon_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0003663"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0003661"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0002101"},{"id":"A40","pred":"uberon_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T189","span":{"begin":90,"end":104},"obj":"Body_part"},{"id":"T190","span":{"begin":288,"end":297},"obj":"Body_part"},{"id":"T191","span":{"begin":443,"end":452},"obj":"Body_part"},{"id":"T192","span":{"begin":453,"end":459},"obj":"Body_part"},{"id":"T193","span":{"begin":478,"end":485},"obj":"Body_part"},{"id":"T194","span":{"begin":526,"end":533},"obj":"Body_part"},{"id":"T195","span":{"begin":556,"end":561},"obj":"Body_part"},{"id":"T196","span":{"begin":570,"end":576},"obj":"Body_part"},{"id":"T197","span":{"begin":598,"end":602},"obj":"Body_part"},{"id":"T198","span":{"begin":685,"end":691},"obj":"Body_part"}],"attributes":[{"id":"A189","pred":"fma_id","subj":"T189","obj":"http://purl.org/sig/ont/fma/fma20110"},{"id":"A190","pred":"fma_id","subj":"T190","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A191","pred":"fma_id","subj":"T191","obj":"http://purl.org/sig/ont/fma/fma7184"},{"id":"A192","pred":"fma_id","subj":"T192","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A193","pred":"fma_id","subj":"T193","obj":"http://purl.org/sig/ont/fma/fma83365"},{"id":"A194","pred":"fma_id","subj":"T194","obj":"http://purl.org/sig/ont/fma/fma83365"},{"id":"A195","pred":"fma_id","subj":"T195","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A196","pred":"fma_id","subj":"T196","obj":"http://purl.org/sig/ont/fma/fma32558"},{"id":"A197","pred":"fma_id","subj":"T197","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A198","pred":"fma_id","subj":"T198","obj":"http://purl.org/sig/ont/fma/fma32558"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T79","span":{"begin":42,"end":47},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T388","span":{"begin":30,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T389","span":{"begin":90,"end":104},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T390","span":{"begin":243,"end":252},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T391","span":{"begin":302,"end":312},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T392","span":{"begin":354,"end":355},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T393","span":{"begin":403,"end":404},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T394","span":{"begin":448,"end":452},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T395","span":{"begin":453,"end":459},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T396","span":{"begin":453,"end":459},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T397","span":{"begin":453,"end":459},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T398","span":{"begin":453,"end":459},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"},{"id":"T399","span":{"begin":478,"end":485},"obj":"http://purl.obolibrary.org/obo/PR_000009054"},{"id":"T400","span":{"begin":526,"end":533},"obj":"http://purl.obolibrary.org/obo/PR_000009054"},{"id":"T401","span":{"begin":551,"end":553},"obj":"http://purl.obolibrary.org/obo/PR_000009064"},{"id":"T402","span":{"begin":570,"end":576},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T403","span":{"begin":570,"end":576},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T404","span":{"begin":570,"end":576},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T405","span":{"begin":570,"end":576},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"},{"id":"T406","span":{"begin":630,"end":633},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T407","span":{"begin":685,"end":691},"obj":"http://purl.obolibrary.org/obo/UBERON_0001630"},{"id":"T408","span":{"begin":685,"end":691},"obj":"http://purl.obolibrary.org/obo/UBERON_0005090"},{"id":"T409","span":{"begin":685,"end":691},"obj":"http://www.ebi.ac.uk/efo/EFO_0000801"},{"id":"T410","span":{"begin":685,"end":691},"obj":"http://www.ebi.ac.uk/efo/EFO_0001949"},{"id":"T411","span":{"begin":831,"end":834},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T483","span":{"begin":350,"end":352},"obj":"Chemical"},{"id":"T486","span":{"begin":478,"end":485},"obj":"Chemical"},{"id":"T487","span":{"begin":526,"end":533},"obj":"Chemical"},{"id":"T488","span":{"begin":551,"end":553},"obj":"Chemical"},{"id":"T489","span":{"begin":562,"end":568},"obj":"Chemical"},{"id":"T490","span":{"begin":577,"end":589},"obj":"Chemical"},{"id":"T491","span":{"begin":653,"end":664},"obj":"Chemical"}],"attributes":[{"id":"A483","pred":"chebi_id","subj":"T483","obj":"http://purl.obolibrary.org/obo/CHEBI_141424"},{"id":"A484","pred":"chebi_id","subj":"T483","obj":"http://purl.obolibrary.org/obo/CHEBI_25573"},{"id":"A485","pred":"chebi_id","subj":"T483","obj":"http://purl.obolibrary.org/obo/CHEBI_1224"},{"id":"A486","pred":"chebi_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/CHEBI_145810"},{"id":"A487","pred":"chebi_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/CHEBI_145810"},{"id":"A488","pred":"chebi_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/CHEBI_74061"},{"id":"A489","pred":"chebi_id","subj":"T489","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A490","pred":"chebi_id","subj":"T490","obj":"http://purl.obolibrary.org/obo/CHEBI_17855"},{"id":"A491","pred":"chebi_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/CHEBI_78665"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T56","span":{"begin":48,"end":56},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T57","span":{"begin":48,"end":56},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T58","span":{"begin":48,"end":56},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T59","span":{"begin":48,"end":56},"obj":"http://purl.obolibrary.org/obo/GO_0001906"},{"id":"T60","span":{"begin":243,"end":252},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T61","span":{"begin":787,"end":809},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T34","span":{"begin":42,"end":47},"obj":"Phenotype"},{"id":"T35","span":{"begin":526,"end":544},"obj":"Phenotype"},{"id":"T36","span":{"begin":603,"end":614},"obj":"Phenotype"}],"attributes":[{"id":"A34","pred":"hp_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0000855"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0004324"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T219","span":{"begin":0,"end":144},"obj":"Sentence"},{"id":"T220","span":{"begin":145,"end":362},"obj":"Sentence"},{"id":"T221","span":{"begin":363,"end":641},"obj":"Sentence"},{"id":"T222","span":{"begin":642,"end":907},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"720","span":{"begin":42,"end":74},"obj":"Gene"},{"id":"721","span":{"begin":76,"end":81},"obj":"Gene"},{"id":"722","span":{"begin":145,"end":150},"obj":"Gene"},{"id":"723","span":{"begin":166,"end":171},"obj":"Gene"},{"id":"724","span":{"begin":216,"end":219},"obj":"Gene"},{"id":"725","span":{"begin":350,"end":355},"obj":"Gene"},{"id":"726","span":{"begin":377,"end":382},"obj":"Gene"},{"id":"727","span":{"begin":478,"end":485},"obj":"Gene"},{"id":"728","span":{"begin":526,"end":533},"obj":"Gene"},{"id":"729","span":{"begin":831,"end":834},"obj":"Gene"},{"id":"730","span":{"begin":630,"end":633},"obj":"Gene"},{"id":"731","span":{"begin":119,"end":123},"obj":"Species"},{"id":"732","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"733","span":{"begin":577,"end":589},"obj":"Chemical"},{"id":"734","span":{"begin":113,"end":118},"obj":"Disease"},{"id":"735","span":{"begin":685,"end":696},"obj":"Disease"}],"attributes":[{"id":"A720","pred":"tao:has_database_id","subj":"720","obj":"Gene:25625"},{"id":"A721","pred":"tao:has_database_id","subj":"721","obj":"Gene:25625"},{"id":"A722","pred":"tao:has_database_id","subj":"722","obj":"Gene:25625"},{"id":"A723","pred":"tao:has_database_id","subj":"723","obj":"Gene:156767"},{"id":"A724","pred":"tao:has_database_id","subj":"724","obj":"Gene:7099"},{"id":"A725","pred":"tao:has_database_id","subj":"725","obj":"Gene:18033"},{"id":"A726","pred":"tao:has_database_id","subj":"726","obj":"Gene:25625"},{"id":"A727","pred":"tao:has_database_id","subj":"727","obj":"Gene:3630"},{"id":"A728","pred":"tao:has_database_id","subj":"728","obj":"Gene:3630"},{"id":"A729","pred":"tao:has_database_id","subj":"729","obj":"Gene:83720"},{"id":"A730","pred":"tao:has_database_id","subj":"730","obj":"Gene:83720"},{"id":"A731","pred":"tao:has_database_id","subj":"731","obj":"Tax:10116"},{"id":"A732","pred":"tao:has_database_id","subj":"732","obj":"MESH:C058787"},{"id":"A733","pred":"tao:has_database_id","subj":"733","obj":"MESH:D014280"},{"id":"A734","pred":"tao:has_database_id","subj":"734","obj":"MESH:D009765"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"MESH:D009135"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Royal jelly downregulated the activity of tumor necrosis factor receptor 1 (TNFR1) in the adipose tissue of aged obese rats receiving HFD [100]. TNFR1 interacts with TNFR2 to negatively regulate toll-like receptors (TLR) and Nod-like receptor signaling and stimulate excessive release of cytokines via activation of key inflammatory pathways such as NF-κB [107]. Mitigation of TNFR1 was associated with a significant increase of the weight of hind limb muscle and reductions in insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), serum lipids, muscle triglyceride levels, body weight gain, and abdominal fat weight. Therefore, royal jelly may protect against muscle loss in conditions involving impairment of the adipokine profile mainly through suppression of inflammatory responses associated with high fat mass, which is followed by correction of metabolic irregularities [100]."}